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Langerhans cells are antigen presenting dendritic cells and tumours arising from these are rare. The tumours arising from these
dendritic cells are divided into two categories according to aWHO classification: Langerhans cell histiocytosis and Langerhans cell
sarcoma. It is the degree of atypia and clinical aggressiveness that distinguishes the two subtypes. Langerhans cell sarcoma (LCS) is
a neoplastic proliferation of Langerhans cells which can occur in skin, bone marrow, lymph nodes, spleen, liver, and lung. LCS can
present with multiple cutaneous and systemic lesions. We present a case of Langerhans cell sarcoma with a unique morphological
appearance and variable immunohistochemical profile within a single cutaneous lesion. LCS is a raremalignancy and its diagnosis is
based onmorphology, immunophenotypical examination, and ultrastructural analysis by electronmicroscopy. Our case highlights
a uniquemorphological description of LCSwherein the pleomorphic neoplastic cells show epidermotropism and are surrounded by
a variable amount of inflammatory infiltrate within a single cutaneous lesion. A single cutaneous lesion of Langerhans cell sarcoma
with variable immunohistochemical profile has not been described so far.
1. Introduction
Langerhans cell sarcoma (LCS) is considered to be a high
grade neoplasm which may present with a single cutaneous
lesion or with extensive systemic involvement [1]. Typically,
involvement of multiple sites is seen [2]. The tumour cells
have an overtly malignant cytomorphology and it is only
the immunophenotype and/or the ultrastructure which may
suggest and confirm Langerhans cell lineage [3]. Primary
cutaneous LCS is very rare andmaking an accurate histologi-
cal diagnosis can be challenging [4]. Langerhans cells express
CD1a, S100, and Langerin (CD207). They also show Birbeck
granules on electron microscopy [5].
A number of differential diagnoses, all of which can have
an overtly malignant cytomorphology, need to be considered
before making a diagnosis of LCS. These include metastatic
carcinoma, malignant melanoma, anaplastic large cell lym-
phoma, pleomorphic dermal sarcoma, atypical fibroxan-
thoma, and myeloid sarcoma [3]. We present a case of LCS
which showsmorphological and immunohistochemical vari-
ability within a single cutaneous lesion of LCS, highlighting
the difficulty of making this rare diagnosis in small punch
biopsies.
2. Case Presentation
A 91-year-old man presented with a long standing 3 cm
plaque on his back which had recently become ulcerated.
This lesion contained three distinct circular areas. The first
area was fleshy, the second area was indurated with some
telangiectasia, and the third area was ulcerated with adjacent
telangiectasia and induration.There was no history of weight
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(a) (b) (c)
Figure 1: Low power H&E images demonstrating variable amount of inflammatory infiltrate around tumour cells and extending into the
subcutaneous tissue in each of the three biopsies (a), (b), and (c).
(a) (b) (c)
Figure 2: High power H&E images demonstrating variable inflammatory infiltrate surrounding neoplastic tumour cells in each of the three
biopsies (a), (b), and (c).
loss, organomegaly, lymphadenopathy, or any other systemic
symptoms. Similar skin lesions were not present elsewhere.
Each of the lesions was biopsied. After a diagnosis of
Langerhans cell sarcoma was made, the patient underwent
a wide local excision of the biopsy site and also underwent
a staging CT scan. Imaging revealed no evidence of involve-
ment of other organ systems. A decision wasmade tomanage
the patient conservatively without further therapeutic inter-
vention. The patient has been followed up for 24 months and
there has been no evidence of recurrent disease.
The biopsies and surgical specimens were fixed in 10%
buffered formalin. These were embedded in paraffin blocks.
Four micron thick sections were cut and stained with haema-
toxylin and eosin (H and E). The antibodies in this study
(CD3, CD30, CD15, CD1a, S100, CD45, CD21, CD68, CD20,
ALK1, CD2, CD7, CD5,HMB-45,MelanA, andMyeloperoxi-
dase)were obtained fromDAKOand the immunohistochem-
istrywas undertaken according to themanufacturer’s instruc-
tions. Langerin immunohistochemistry was undertaken at a
referral centre. A portion of the tumour was submitted for
electron microscopic examination.
Each biopsy showed a dermal infiltrate composed of
highly atypical cells with abundant cytoplasm and bizarre
nuclei, complex nuclear membrane infolding, and prominent
nucleoli. The tumour cells were seen extending into the
subcutaneous tissue. The neoplastic cells also showed epi-
dermotropism. There were numerous mitoses and a variable
chronic inflammatory infiltratewas admixedwith the tumour
cells (Figures 1 and 2). The tumour cells in all three biopsies
were positive for CD1a and Langerin (Figure 3). Tumour cells
from the first area biopsied were strongly positive for S100,
whereas the cells from the second area biopsied showed weak
positivity for S100 and from the third area they were negative
with S100 (Figure 4). There was equivocal staining in the first
and second biopsies with CD45 but strong positive staining
in the third biopsy (Figure 5).
Myeloperoxidase, CD21, CD68, CD20, CD3, CD30,
CD15, Alk1, CD2, CD7, CD5, CD56, and pan melanoma
cocktail (HMB45 and Melan A) were negative. The stain-
ing for Mib1 revealed heterogeneity in the proportion of
tumour cells staining with this antibody within the dermal
and intraepidermal components of the tumour. Focally the
dermal component shows 50–80%positivity.The intradermal
component cannot be accurately enumerated because of the
sparsity of the tumour cells and also because an absolute
distinction cannot be made from staining in epithelial cells
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Figure 3: Langerin immunohistochemistry highlights tumour cells at the three biopsy sites (a), (b), and (c).
(a) (b) (c)
Figure 4: S100 immunohistochemistry positivity was variable in the three biopsies; these images compare the S100 positivity from the three
different biopsy sites. (a) shows that tumour cells are S100 positive; (b) shows that occasional tumour cells are S100 positive; (c) shows that
tumour cells are negative for S100. This variability within a single cutaneous lesion has not been reported within a single LCS lesion.
(a) (b) (c)
Figure 5: CD45 immunohistochemistry. Biopsies from the first (a) and second site (b) were positive whereas the biopsy from the third site
(c) was negative.
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Figure 6: Electron microscopy demonstrates Birbeck granules. Birbeck granules are racquet or rod shaped cell organelles which are a
characteristic feature of Langerhans cell.The presence of these on ultrastructural analysis confirms that the cell of origin is from the dendritic
cell family.
without recourse to double labelling with CD1a and Mib1
which we are unable to do. The presence of Birbeck gran-
ules was confirmed by electron microscopy, confirming the
Langerhans cell lineage of the tumour (Figure 6).
The excision specimen was a skin ellipse with underlying
fat (5 cm × 4 cm × 4 cm) and contained several discrete
plaques with a central bluish area. Tumour invaded to a depth
of 6mm. There was similar morphological and immuno-
phenotypical variability in the tumour cells as seen in the
biopsies. Histology showed that the surgical margins were
clear by 4mm.
3. Discussion
LCS is an extremely rare tumour arising from Langerhans
cells; these cells are part of the dendritic cell family and
their primary role is antigen capture and presentation [6].
These cells are normally found in the epidermis and also
along with the mucosal lining of the oral cavity, pharynx,
oesophagus, upper airways, urethra, and female reproductive
tract [6]. LCS has a high degree of cytological atypia and
usually a clinically aggressive course [2]; most cutaneous
Langerhans cell sarcomas are described as having large
atypical cells, some of which have an epithelioid appearance
with pleomorphic nuclei; these are usually found in the
dermis and the subcutaneous tissue [4]. In this case, mor-
phologically the lesion contained pleomorphic bizarre cells
with epidermotropism which has so far not been described
in cutaneous Langerhans cell sarcoma. The tumour cells
in LCS are reported to express CD1a, S100, and Langerin
[7]. These tumours may arise de novo or may complicate
myeloproliferative disorders and also rarely Langerhans cell
histiocytosis [2]. Bohn et al. reviewed a total of 20 cases and
reported that purely cutaneous presentation was seen in only
three cases whilst the remaining cases showed involvement of
both the skin and other organ systems [4]. Complete absence
of expression of S100 has been reported in one case [4].
Three other cases showed equivocal staining [4]. Of note,
there was evidence of significant intralesional heterogeneity
in the immunophenotype of the tumour cells in this case.This
variability seen with S100 and CD45 staining has not been
reported previously in a LCS lesion.
It is of interest that there was a variable degree of chronic
inflammation associated with the tumour in each of the
biopsies raising the possibility of a host chronic inflammatory
cell response to the neoplasm.
Although S100 negative cells have been described in pre-
vious case reports [4], a review of cases suggests that a large
proportion of tumours will show S100 positivity inmore than
50% of the neoplastic cells [7]. This immunohistochemical
variability within a single lesion could potentially make the
diagnosis of LCSmore challenging. In our case, the neoplastic
cells were positive with CD1a and Langerin.
Our case highlights a number of unique features of
cutaneous Langerhans cell sarcoma. The presence of a long-
standing plaque may hypothetically indicate the possibility
of an initial in situ lesion prior to invasion into the dermis
and subcutaneous tissue. This case demonstrates a unique
morphology of Langerhans cell sarcoma with large atypi-
cal pleomorphic cells demonstrating epidermotropism with
tumour cells surrounded by a variable amount of inflamma-
tory infiltrate within the dermis. The immunohistochemical
variability seen within this single cutaneous lesion highlights
that the immunohistochemical profile of this tumour may
still be incomplete and the immunohistochemical variability
could potentially make this diagnosis challenging if a limited
panel of antibodies is used.
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